Review
Oncology
Ryan M. Finnegan, Ahmed M. Elshazly, Patricia Schoenlein, David A. Gewirtz
Summary: This article reviews the relationship between endocrine therapies and autophagy, exploring the different functional roles of autophagy in response to these treatments. It is found that autophagy can have cytoprotective, non-protective, cytostatic, or cytotoxic effects on tumor cells, suggesting its potential as an adjuvant therapeutic modality for endocrine therapies.
Review
Biochemistry & Molecular Biology
Lea Clusan, Francois Ferriere, Gilles Flouriot, Farzad Pakdel
Summary: Breast cancer, the most common and deadliest cancer among women worldwide, is closely associated with estrogen signaling. Hormone therapy using antiestrogens is the standard treatment, but resistance inevitably occurs through various biological mechanisms. Understanding the estrogen pathway is crucial for the development of new therapies for hormone-dependent breast cancer. This mini-review summarizes the current literature on estrogen receptors in breast cancer, including their signalization, mechanisms of action, and clinical implications.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Oncology
Maria Sund, Hans Garmo, Anne Andersson, Sara Margolin, Johan Ahlgren, Antonis Valachis
Summary: This study investigates the impact of estrogen therapy on breast cancer mortality risk in women receiving adjuvant endocrine treatment. The results suggest that concurrent use of estrogen therapy with endocrine treatment, either in the short term or long term, does not significantly increase the risk of breast cancer mortality.
BREAST CANCER RESEARCH AND TREATMENT
(2023)
Review
Endocrinology & Metabolism
Esmael Besufikad Belachew, Dareskedar Tsehay Sewasew
Summary: The estrogen receptor is crucial in the treatment of estrogen receptor-positive breast cancer, with endocrine resistance posing a challenge. Combining drugs that target different signaling pathways and coregulatory proteins with endocrine therapy may offer a novel therapeutic approach to combat endocrine resistance.
FRONTIERS IN ENDOCRINOLOGY
(2021)
Article
Chemistry, Inorganic & Nuclear
Xiao-Meng Liu, Zhe Li, Xin-Rui He, Rui-Ping Liu, Zhong-Ying Ma, Xin Qiao, Shu-Qing Wang, Jing-Yuan Xu
Summary: The study designed and prepared a new class of multi-targeting Pt(IV) prodrugs using the FDA-approved aromatase inhibitor aminoglutethimide, with a representative compound aminoplatin 3 showing enhanced anticancer activity and lower toxicity compared to cisplatin in ER-positive MCF-7 cells.
INORGANIC CHEMISTRY FRONTIERS
(2022)
Article
Biochemistry & Molecular Biology
Manisha du Plessis, Carla Fourie, Wendy Stone, Anna -Mart Engelbrecht
Summary: The incidence of breast cancer is associated with geographic variation, suggesting that the surrounding environment plays a crucial role in cancer development. Exposure to wastewater, which contains pathogens, mutagens, and carcinogens, is an environmental risk factor for breast cancer. Wastewater can also contain trace amounts of chemical pollutants, including toxic metals and pesticides, that can mimic estrogen and increase the risk of estrogen-receptor (ER) positive breast cancer. Strategies should be implemented to limit exposure and regulate the production and use of harmful chemicals.
Review
Oncology
Jing Xu, Bo Cao, Chunyu Li, Guohui Li
Summary: Breast cancer is a global health concern. Endocrine therapy is crucial in treating estrogen-positive breast cancer, but it often leads to osteoporosis-related adverse events. These events increase the risk of fractures and reduce the patients' quality of life. This review explores the possibility of endocrine therapy-induced osteoporosis in estrogen-positive breast cancer treatment and discusses the mechanisms involved and the potential of drug therapies and combinations.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
G. Jerusalem, S. Farah, A. Courtois, J. Chirgwin, S. Aebi, P. Karlsson, P. Neven, E. Hitre, M. P. Graas, E. Simoncini, E. Abdi, C. Kamby, A. Thompson, S. Loibl, J. Gavila, K. Kuroi, C. Marth, B. Muller, S. O'Reilly, A. Gombos, T. Ruhstaller, H. J. Burstein, M. Rabaglio, B. Ruepp, K. Ribi, G. Viale, R. D. Gelber, A. S. Coates, S. Loi, A. Goldhirsch, M. M. Regan, M. Colleoni
Summary: The study found that extended adjuvant therapy with intermittent administration of letrozole did not improve 7-year disease-free survival compared to continuous treatment, despite the recovery of estrogen levels. Adverse events rates were similar in both groups.
ANNALS OF ONCOLOGY
(2021)
Review
Pathology
Shi Wei
Summary: Breast cancer is the most common cancer affecting women, and estrogen receptor (ER) signaling plays a crucial role in its development. ER expression levels are strongly correlated with the therapeutic effects of endocrine therapies targeting ER. Controversies exist regarding the biology and prognostic power of progesterone receptor (PR) status, especially in uncommon subtypes of breast cancer.
PATHOLOGY RESEARCH AND PRACTICE
(2023)
Article
Cell Biology
Fahmida Rasha, Monica Sharma, Kevin Pruitt
Summary: The most common subtype of BC is characterized by ER expression, with treatment typically involving suppression of estrogen production or hindering estrogen binding to its receptors. Despite the benefits of endocrine therapy, overcoming resistance driven by complex changes in the tumor microenvironment remains a clinical challenge, highlighting the need for further investigation into ER modulation mechanisms.
MOLECULAR AND CELLULAR ENDOCRINOLOGY
(2021)
Review
Biochemistry & Molecular Biology
Lea Clusan, Pascale Le Goff, Gilles Flouriot, Farzad Pakdel
Summary: Breast cancer is the most common cancer among women worldwide. While most ER-positive breast cancer cases initially respond to antiestrogen therapies, a high percentage develop resistance over time. Research on mutated forms of ER alpha has led to potential developments in new antiestrogen treatments.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Review
Endocrinology & Metabolism
Jie Yuan, Li Yang, Zhi Li, Hua Zhang, Qun Wang, Jun Huang, Bei Wang, Chakrabhavi Dhananjaya Mohan, Gautam Sethi, Geng Wang
Summary: Endocrine therapy is essential for hormone-positive breast cancers, but resistance to therapy poses a significant challenge. Understanding the molecular mechanisms of resistance and the tumor microenvironment is crucial for developing new treatment strategies.
FRONTIERS IN ENDOCRINOLOGY
(2023)
Article
Environmental Sciences
Juan P. Munoz, Rocio Araya-Osorio, Raul Mera-Adasme, Gloria M. Calaf
Summary: Recent reports have questioned the safety of glyphosate, the active ingredient in several herbicide formulations, suggesting that it may act as an endocrine disruptor by promoting estrogenic activity. This study aimed to investigate the mechanism by which glyphosate induces estrogenic effects using breast cancer cell line models. The results showed that high concentrations of glyphosate mimic the effects of estrogen, leading to the activation of estrogen receptor alpha and enhanced cell proliferation.
Article
Oncology
Charly Jehanno, Pascale Le Goff, Denis Habauzit, Yann Le Page, Sylvain Lecomte, Estelle Lecluze, Frederic Percevault, Stephane Avner, Raphael Metivier, Denis Michel, Gilles Flouriot
Summary: Hormone receptor positive breast cancer often develops resistance to treatment, leading to metastatic relapses. Understanding the molecular mechanisms behind this resistance is crucial. Hypoxia, a common feature of solid tumors, has been shown to promote endocrine resistance by down-regulating estrogen receptor alpha (ER alpha) expression.
Article
Oncology
Javier A. Menendez, Adriana Papadimitropoulou, Travis Vander Steen, Elisabet Cuyas, Bharvi P. Oza-Gajera, Sara Verdura, Ingrid Espinoza, Luciano Vellon, Inderjit Mehmi, Ruth Lupu
Summary: The study highlights the critical role of fatty acid synthase (FASN) in HER2-driven tamoxifen resistance and suggests that FASN inhibition could be a novel therapeutic approach to restore tamoxifen sensitivity in endocrine-resistant breast cancer.urther research using next-generation FASN inhibitors may be therapeutically relevant in countering resistance to tamoxifen in FASN-overexpressing ER+/HER2+ breast carcinomas.
Article
Medicine, General & Internal
Per E. Lonning, Elisabet O. Berge, Merete Bjornslett, Laura Minsaas, Ranjan Chrisanthar, Hildegunn Hoberg-Vetti, Cecile Dulary, Florence Busato, Silje Bjorneklett, Christine Eriksen, Reidun Kopperud, Ulrika Axcrona, Ben Davidson, Line Bjorge, Gareth Evans, Anthony Howell, Helga B. Salvesen, Imre Janszky, Kristian Hveem, Pal R. Romundstad, Lars J. Vatten, Jorg Tost, Anne Dorum, Stian Knappskog
ANNALS OF INTERNAL MEDICINE
(2018)
Article
Oncology
Katharina Bischof, Stian Knappskog, Ingunn Stefansson, Emmet Martin McCormack, Jone Trovik, Henrica Maria Johanna Werner, Kathrine Woie, Bjorn Tore Gjertsen, Line Bjorge
Article
Multidisciplinary Sciences
E. Birkeland, S. Zhang, D. Poduval, J. Geisler, S. Nakken, D. Vodak, L. A. Meza-Zepeda, E. Hovig, O. Myklebost, S. Knappskog, P. E. Lonning
NATURE COMMUNICATIONS
(2018)
Article
Oncology
Aziz Aiderus, Michael A. Black, Anita K. Dunbier
Article
Biochemistry & Molecular Biology
Sam A. Jamieson, Zheng Ruan, Abigail E. Burgess, Jack R. Curry, Hamish D. Mcmilan, Jodi L. Brewster, Anita K. Dunbier, Alison D. Axtman, Natarajan Kannan, Peter D. Mace
Letter
Oncology
Per Eystein Lonning, Stian Knappskog
CLINICAL EPIGENETICS
(2018)
Article
Oncology
Line Pedersen, Pouda Panahandeh, Muntequa I. Siraji, Stian Knappskog, Per Eystein Lonning, Ruth Gordillo, Philipp E. Scherer, Anders Molven, Knut Teigen, Nils Halberg
Article
Multidisciplinary Sciences
Deepak Poduval, Zuzana Sichmanova, Anne Hege Straume, Per Eystein Lonning, Stian Knappskog
Article
Oncology
Deepak B. Poduval, Elisabet Ognedal, Zuzana Sichmanova, Eivind Valen, Gjertrud T. Iversen, Laura Minsaas, Per E. Lonning, Stian Knappskog
CLINICAL EPIGENETICS
(2020)
Article
Genetics & Heredity
B. Liv Gansmo, A. Benedicte Lie, Marthe T. Maehlen, Lars Vatten, Pal Romundstad, Kristian Hveem, Per E. Lonning, Stian Knappskog
Summary: The study found a potential association between the MDM2 del1518 variant and the risk of rheumatoid arthritis, as well as indications that combinational genotypes and haplotypes in the MDM2 locus may be related to rheumatoid arthritis.
Article
Multidisciplinary Sciences
Liv B. Gansmo, Nigar Sofiyeva, Merete Bjornslett, Pal Romundstad, Kristian Hveem, Lars Vatten, Anne Dorum, Per E. Lonning, Stian Knappskog
Summary: The germline deletion of APOBEC3A/B is associated with a reduced risk of ovarian cancer, particularly in non-serous and serous cases. Validation from an independent dataset shows similar trends, with a significant risk reduction observed in clear cell cancers.
SCIENTIFIC REPORTS
(2021)
Article
Oncology
Nigar Sofiyeva, Camilla Krakstad, Mari K. Halle, Tracy A. O'Mara, Pal Romundstad, Kristian Hveem, Lars Vatten, Per E. Lonning, Liv B. Gansmo, Stian Knappskog
Summary: The APOBEC3A/B deletion variant is associated with a decreased risk of endometrial cancer in Norwegian women.
Article
Oncology
Cecilie Fredvik Torkildsen, Liv Cecilie Vestrheim Thomsen, Ragnar Kvie Sande, Camilla Krakstad, Ingunn Stefansson, Eva Karin Lamark, Stian Knappskog, Line Bjorge
Summary: In this study, phenotypic markers were combined with targeted DNA sequencing to discover novel biomarkers for guiding surgical management in high-grade serous ovarian carcinoma (HGSOC) patients. The study highlights the potential of a preoperative risk stratification model combining phenotypic traits and single-gene mutational status in predicting surgical outcomes.
Article
Oncology
Liv B. Gansmo, Paal Romundstad, Kristian Hveem, Lars Vatten, Serena Nik-Zainal, Per Eystein Lonning, Stian Knappskog
Article
Oncology
Lucy R. Yates, Stian Knappskog, David Wedge, James H. R. Farmery, Santiago Gonzalez, Inigo Martincorena, Ludmil B. Alexandrov, Peter Van Loo, Hans Kristian Haugland, Peer Kaare Lilleng, Gunes Gundem, Moritz Gerstung, Elli Pappaemmanuil, Patrycja Gazinska, Shriram G. Bhosle, David Jones, Keiran Raine, Laura Mudie, Calli Latimer, Elinor Sawyer, Christine Desmedt, Christos Sotiriou, Michael R. Stratton, Anieta M. Sieuwerts, Andy G. Lynch, John W. Martens, Andrea L. Richardson, Andrew Tutt, Per Eystein Lonning, Peter J. Campbell